Clinical Trial Update: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 window-of-opportunity trial in premenopausal patients with ER-positive, HER2-negative early breast cancer comparing giredestrant with or without tript…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Giredestrant (giredestrant)
• Triptorelin (triptorelin)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED